

Conclusions Obsessive symptoms could be presented as a part of schizophrenia. Clozapine could worsen this symptoms and it is necessary to adjust its dose to the minimum effective dose.

Disclosure of interest The authors have not supplied their declaration of competing interest.

<http://dx.doi.org/10.1016/j.eurpsy.2016.01.2122>

EV1138

Treatment of schizophrenia with aripiprazole may contribute to improved functions

A. Björner^{1,*}, N. Erixon-Lindroth², S. Öberg Jansdotter³, A. Flatla⁴

¹ Gothenburgh, Sweden

² Otsuka Pharmaceuticals, Scandinavia, Stockholm, Sweden

³ Bristol-Myers Squibb at time of study, Stockholm, Sweden

⁴ Bristol-Myers Squibb, Oslo, Norway

* Corresponding author.

Introduction The goals with modern treatment of schizophrenia are to achieve remission of clinical symptoms, prevent relapse, and to restore the patients' functions.

Objectives/aims The objective of this study was to investigate the impact of treatment with the partial dopamine agonist aripiprazole on functions, measured as time spent for work or studies, in patients with schizophrenia or schizoaffective disorder.

Methods Retrospective data on employment and study activities were collected for all patients between 18–65 years with schizophrenia or schizoaffective disorder at an open care psychosis clinic in Sweden ($n = 104$). Possible impact of treatment with aripiprazole and of other variables, such as age, gender, and disease severity, was analysed.

Results Among patients who worked or studied at Day of admission ($n = 36$), the probability of maintaining or increasing time for work or studies was significantly higher in patients treated with aripiprazole compared with patients who were not (88% versus 53%; $P = 0.020$). This difference remained significant after controlling for severity of symptoms, age and sex. A secondary analysis, including all patients (independent of work or study status at Day of admission) also showed a significant difference in favour of aripiprazole (53% versus 26%, $P = 0.005$).

Conclusions The results indicate that patients treated with aripiprazole (monotherapy or add-on) have higher probability of maintaining functional capacity. A plausible explanation might be aripiprazole's favourable effect on cognitive functions.

Disclosure of interest The authors have not supplied their declaration of competing interest.

<http://dx.doi.org/10.1016/j.eurpsy.2016.01.2123>

EV1140

A comprehensive systematic screening protocol for assessment of medical comorbidities in schizophrenia

P. Bucci^{1,*}, E. Durante Mangoni², P.C. Pafundi², S. De Simone¹, U. Malgeri², A. Mucci¹, S. Galderisi¹, M. Maj¹

¹ University of Naples SUN, Department of Psychiatry, Naples, Italy

² University of Naples SUN, Internal Medicine Section, Department of Cardiothoracic Sciences, and Division of Infectious and Transplant Medicine, Naples, Italy

* Corresponding author.

Introduction Difficult access and low quality of health care are recognized as factors that may account for the excess deaths widely reported in patients with schizophrenia. As a matter of fact, psychiatrists not always possess adequate competences in the assessment of physical health, while non-psychiatric physicians receive little

training in psychiatry and are not prepared to take care of subjects with severe mental illnesses.

Objectives We present a comprehensive and systematic algorithm for screening medical comorbidities, conceived to be easy to use for psychiatrists, after a brief training.

Aims The study is aimed to implement an instrument for proper detection and management of physical illnesses in people with schizophrenia.

Methods The screening protocol, developed by internal medicine specialists, was applied to 15 subjects in two independent assessments, one performed by trainees in psychiatry, after a brief training, and one carried out by one specialist and two trainees in internal medicine. The analysis of the inter-rater reliability was carried out by calculating the Cohen's kappa coefficient and the intraclass correlation coefficient as appropriate.

Results The agreement among raters resulted excellent for 61% of items, good for 17%, moderate for 18% and scarce for 4%. The few items showing scarce inter-rater reliability were excluded. The final algorithm is being tested for feasibility in psychiatric settings.

Conclusions The proposed screening protocol resulted in a suitable tool, showing moderate to excellent inter-rater reliability, that can be used in clinical practice by psychiatrists after a brief training.

Disclosure of interest The authors have not supplied their declaration of competing interest.

<http://dx.doi.org/10.1016/j.eurpsy.2016.01.2125>

EV1142

Internalized stigma, negative symptoms and global functioning in schizophrenia

O.O. Căpatina*, I.V. Miclutia

University of Medicine and Pharmacy "Iuliu Hatieganu" Cluj-Napoca, Neuroscience Psychiatry, Cluj-Napoca, Romania

* Corresponding author.

Introduction Negative symptoms (NS) of schizophrenia were usually described as a unitary construct and as a separable domain of pathology; however recent studies suggest, that they encompass 2 separable domains: Diminished Expression (DE) and Avolition-Apathy (AA). Research into the relationship between internalized stigma and NS have yielded mixed results up to present.

Objective The objectives of this study was to assess the factor structure of NS and to examine the relationship between these factors and internalized stigma, global functioning and sociodemographic characteristics.

Aims The broad aim of this study was to gather greater understanding of the relationship between internalized stigma, NS and global functioning.

Methods A sample of 50 consecutive subjects were recruited from outpatient psychiatric hospitals meeting the criteria for schizophrenia according to ICD-10. The patients were evaluated using the Positive and Negative Symptoms Scale (PANSS), Negative Symptoms Assessment-16 items (NSA-16), Global Assessment of Functioning (GAF), Clinical Global Impression-Severity Scale (CGI-s), Internalized Stigma of Mental Illness Scale (ISMI) and were interviewed to assess sociodemographic characteristics.

Results A two-factor structure for the domain of NS was found: an AA and DE profile group. AA and DE subgroups significantly differed on clinically relevant external validators and greater resistance to stigma is related to both fewer AA and DE symptoms in people with schizophrenia.

Conclusions Our findings suggest that the different subdomains of NS can be identified within the broader diagnosis of schizophrenia and that they should be analyzed as distinct domains and that stigma resistance can be a possible intervention target to ameliorate NS.